Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
about
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationSurvey of the perceptions of key stakeholders on the attributes of the South African Notifiable Diseases Surveillance SystemGlutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.Targeting the ATR-CHK1 Axis in Cancer TherapyEmerging targets for radioprotection and radiosensitization in radiotherapy.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.Differential cell-matrix responses in hypoxia-stimulated aortic versus mitral valves.Expression and clinical significance of ATM and PUMA gene in patients with colorectal cancer.PARP inhibitors: Clinical utility and possibilities of overcoming resistance.Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways
P2860
Q26771165-32C2E9A8-1354-4B89-949D-46082601EBB1Q27928041-0D586763-D248-474C-9AD3-96E6F0063EB1Q30313120-9E9EEF3D-2E8A-4903-B157-895C6588C040Q35595719-70CFCCA0-B78D-46FA-811D-D9FB683E06BFQ35799909-31567DE8-81F1-47FB-9636-67A8FD20C54EQ36688959-4230E336-8134-47BF-9F01-645B72EA2C31Q37295535-3E1F17AF-01C6-4326-A7C4-5115920C4D60Q38714246-5338D772-6BD3-49E9-8CF9-33004E308B7FQ38817102-E477E36D-626C-4084-A453-C8F2183299BAQ38869603-12BB2651-4FFB-431E-943B-99FA979598B4Q39433258-3301FD7B-E9FD-468E-BC5A-83819A8BED34Q42292342-8B5A846C-79BF-4DAC-B620-FBC01A9BA3DAQ45848384-437F6C37-DEE2-44A6-9456-D1D986FAFA85Q46154004-4E55A025-E296-40A2-A1E7-9A7EDB93D5B3Q49469982-69B659EC-B1FC-43AB-B272-B44F1F487B2DQ50076626-E37B53CF-4BD4-4FDE-A56D-A509F3917940Q58695632-C55788BF-5B81-4F5E-AB8A-69B3C759DA80
P2860
Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@ast
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@en
type
label
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@ast
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@en
prefLabel
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@ast
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@en
P2093
P2860
P1433
P1476
Pharmacologic inhibition of AT ...... al, and cervical cancer cells.
@en
P2093
Chad A Hamilton
Christopher J Bakkenist
George Larry Maxwell
Kathleen M Darcy
Nicholas W Bateman
Pang-ning Teng
Thomas P Conrads
P2860
P304
P356
10.1016/J.YGYNO.2014.12.035
P407
P577
2015-01-02T00:00:00Z